In this online CME self-learning program:
Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that is defined by a transmural process that often occurs in the terminal ileum but may occur in any portion of the GI tract. Although the exact etiology of CD is unknown, a handful of genetic, immunological, and environmental risk factors have been identified. Research suggests that in genetically susceptible patients, there is an impaired immune response to commensal or pathogenic intestinal microbiota that drives mucosal inflammation. The incidence of pediatric CD (pCD) is increasing around the globe, varying between 2.5 to 11.4 per 100,000, with an estimated prevalence of 58 per 100,000. Approximately 25% of patients are diagnosed with IBD before the age of 18. Intestinal and abdominal complications such as strictures, abscesses, and fistulas are common among pediatric patients and increase as the disease progresses. IBD impairs attendance at school, and psychosocial ramifications in children diagnosed with IBD incdude a higher incidence of depression and anxiety.
The following healthcare professionals: pediatricians and pediatric gastroenterologists; physician assistants, nurse practitioners, nurses, and pharmacists; and any other healthcare professionals with an interest in or who clinically encounter patients with pCD.
This program is supported by an educational grant from Abbott Nutrition.
This activity is free of charge.
Release Date: May 24, 2019 -- Expiration Date: May 24, 2021
Faculty: Dinesh Pashankar, MD
Epidemiology and clinical features of pCD
Treatment of pCD
By the end of the session the participant will be able to:
ACCME Activity #201336468ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Dinesh S. Pashankar, MD, discloses financial support (research grant) from Janssen and Abbvie.
Disclosures of Educational Planners: Charles Turck, PharmD has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by an educational grant from Abbott Nutrition.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Medical and nutritional management of eosinophilic esophagitis in adolescents and adults: Therapeutic updates and best practices
The current and emerging landscape of pediatric growth hormone deficiency (GHD) pharmacotherapy
The Current and Emerging Landscape of Pharmacotherapy for Neonatal Respiratory Distress Syndrome (NRDS)